SPDL1 and non-small cell lung carcinoma: Among 233 NSCLC patients treated with αPD‐1 agents, those with elevated baseline serum sPD‐L1 (≥90 pg/mL) had shorter mPFS (57 vs. 177 days) and mOS (182 days vs. not reached at 1200 days).41